- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Eyetech to help MDs get reimbursed for Macugen
New York—Eyetech Pharmaceuticals Inc. is offering to help physicians and patients seeking Medicare reimbursement for pegaptanib sodium injection (Macugen) treatment.
New York-Eyetech Pharmaceuticals Inc. is offering to help physicians and patients seeking Medicare reimbursement for pegaptanib sodium injection (Macugen) treatment.
The company has introduced its Macugen Access Program (MAP), which offers pre-treatment and post-treatment services, including insurance verification, authorization assistance, claims and reviews tracking, denials and appeal assistance, and patient assistance programs for insured and uninsured patients.
The MAP hotline is 866/272-8838.
The product, which is used for the treatment of neovascular age-related macular degeneration, was launched Jan. 20.
